About According to WHO, CKD is not only common, treatable, and harmful but also a major contributing factor to the incidence and outcomes of at least three of the diseases that are targeted by WHO (hypertension, diabetes, and CVD). CKD is mainly defined as a reduced GFR, increased urinary albumin excretion, or both, and is growing public health issue. CKD is classified into five stages (stages 1-5) according to renal function and the level of urinary protein excretion as measured by eGFR which is derived from race, gender, age, and serum creatinine concentration.
TechNavio's analysts forecast the Global CKD Drugs market to grow at a CAGR of 1.21 percent over the period 2014-2019.
TechNavio's analysts forecast the Global CKD Drugs market to grow at a CAGR of 1.21 percent over the period 2014-2019.
Request For Sample Report @ https://www.wiseguyreports.com/sample-request/38597-global-chronic-kidney-disease-ckd-drugs-market-2015-2019
Covered in this Report The Global CKD Drugs Market can be divided into two segments: Route of Administration which includes oral, SC, and IV and Mechanism of Action which includes ARBs, ACEIs, ESAs, PH Binders, and Vasodilators. This report covers the present scenario and the growth prospects of the Global CKD Drugs market for the period 2014–2019. To calculate the market size, the report considers the revenue generated from the sales of various drugs used in the treatment of CKD that are available in the market.
TechNavio's report, the Global CKD Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, the EMEA and APAC regions; it also covers the Global CKD Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Regions • Americas
• EMEA
• APAC
• EMEA
• APAC
Key Vendors • Actavis PLC
• Amgen Inc.
• Johnson & Johnson
• F. Hoffmann-La Roche Ltd
• Amgen Inc.
• Johnson & Johnson
• F. Hoffmann-La Roche Ltd
• Sanofi
Other Prominent Vendors • Abbott Laboratories
• Akebia Therapeutics
• AMAG Pharmaceuticals
• Cara Therapeutics
• FibroGen
• Keryx Biopharmaceuticals
• Reata Pharmaceuticals
• OPKO Health
• Pharmacosmos
• Raptor Pharmaceuticals
• Regulus Therapeutics
• Rockwell Medical
• Shield Therapeutics
• Takeda Pharmaceuticals
• Vifor Pharma Ltd
• Xenetic Biosciences
• ZS Pharma
Market Driver • Increase in Associated Disorders with CKD
• For a full, detailed list, view our report
• Akebia Therapeutics
• AMAG Pharmaceuticals
• Cara Therapeutics
• FibroGen
• Keryx Biopharmaceuticals
• Reata Pharmaceuticals
• OPKO Health
• Pharmacosmos
• Raptor Pharmaceuticals
• Regulus Therapeutics
• Rockwell Medical
• Shield Therapeutics
• Takeda Pharmaceuticals
• Vifor Pharma Ltd
• Xenetic Biosciences
• ZS Pharma
Market Driver • Increase in Associated Disorders with CKD
• For a full, detailed list, view our report
Market Challenge • Genericization of Major Brands
• For a full, detailed list, view our report
• For a full, detailed list, view our report
Market Trend • Approval of New Pipeline Drugs
• For a full, detailed list, view our report
• For a full, detailed list, view our report
Key Questions Answered in this Report • What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
Complete Report Details @ https://www.wiseguyreports.com/reports/38597-global-chronic-kidney-disease-ckd-drugs-market-2015-2019
Table of Contents
- Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Product Profiles
04.1.1 Aranesp
04.1.2 Epogen/Procrit
04.1.3 Mircera
04.1.4 Renvela
04.1.5 Avapro
04.1.6 Bystolic
05. Market Research Methodology
05.1 Market Research Process
05.2 Research Methodology
06. Introduction
07. Disease Overview
07.1 Etiology
07.2 Epidemiology
07.2.1 Mortality
07.2.2 Prevalence of CKD
08. Pipeline Analysis
08.1 Emerging Treatment Options
09. Market Landscape
09.1 Market Overview
09.2 Market Size and Forecast
09.3 Five Forces Analysis
10. Segmentation of Global CKD Market by Route of Administration
10.1 Oral
10.2 SC
10.3 IV
11. Segmentation of Global CKD Market by Mechanism of Action
11.1 ARBs
11.2 ACEIs
11.3 ESAs
11.4 PH Binders
11.5 Vasodilators
12. Geographical Segmentation
12.1 CKD Drugs Market in Americas
12.1.1 Market Size and Forecast
12.2 CKD Drugs Market in EMEA Region
12.2.1 Market Size and Forecast
12.3 CKD Drugs Market in APAC Region
12.3.1 Market Size and Forecast
13. Buying Criteria
14. Market Growth Drivers
15. Drivers and their Impact
16. Market Challenges
17. Impact of Drivers and Challenges
18. Market Trends
19. Trends and their Impact
20. Vendor Landscape
20.1 Competitive Scenario
20.1.1 Key News
20.1.2 Mergers and Acquisitions
20.2 Market Share Analysis 2014
20.2.1 Competitive Assessment of Top Drugs Used for CKD Treatment
20.2.2 Amgen
20.2.3 Actavis
20.2.4 Johnson & Johnson
20.2.5 F. Hoffmann-La Roche
20.2.6 Sanofi
20.3 Other Prominent Vendors
21. Key Vendor Analysis
21.1 Amgen 21.1.1 Key Facts
21.1.2 Business Overview
21.1.3 Business Segmentation by Revenue 2013
21.1.4 Product Portfolio by Revenue 2013
21.1.5 Business Segmentation by Revenue 2012 and 2013
21.1.6 Geographical Segmentation by Revenue 2013
21.1.7 Business Strategy
21.1.8 Recent Developments
21.1.9 SWOT Analysis
21.2 Actavis 21.2.1 Key Facts
21.2.2 Business Description
21.2.3 Business Segmentation
21.2.4 Business Segmentation by Revenue 2012 and 2013
21.2.5 Sales by Geography
21.2.6 Business Strategy
21.2.7 Key Information
21.2.8 SWOT Analysis
21.3 Johnson & Johnson 21.3.1 Key Facts
21.3.2 Business Overview
21.3.3 Business Segmentation by Revenue 2013
21.3.4 Business Segmentation by Revenue 2012 and 2013
21.3.5 Geographical Segmentation by Revenue 2013
21.3.6 Business Strategy
21.3.7 Recent Developments
21.3.8 SWOT Analysis
21.4 F. Hoffmann-La Roche Ltd. 21.4.1 Key Facts
21.4.2 Business Overview
21.4.3 Business Segmentation
21.4.4 Business Segmentation by Revenue 2012 and 2013
21.4.5 Sales by Geography
21.4.6 Business Strategy
21.4.7 Key Information
21.4.8 SWOT Analysis
21.5 Sanofi SA 21.5.1 Key Facts
21.5.2 Business Description
21.5.3 Business Segmentation
21.5.4 Revenue by Business Segmentation
21.5.5 Revenue Comparison 2012 and 2013
21.5.6 Sales by Geography
21.5.7 Business Strategy
21.5.8 Key Developments
21.5.9. SWOT Analysis
22. Other Reports in this Series
Continued…….
CONTACT US:
NORAH TRENT
Partner Relations & Marketing Manager
sales@wiseguyreports.com
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
No comments:
Post a Comment